Navigation Links
Roper Industries Announces Record Third Quarter Results
Date:10/25/2007

726,881

Deferred taxes 199,955 169,994

Other liabilities 44,675 23,996

Total liabilities 1,538,877 1,508,520

STOCKHOLDERS' EQUITY:

Common stock 909 900

Additional paid-in capital 749,312 717,751

Retained earnings 879,093 721,899

Accumulated other comprehensive

earnings 105,988 68,666

Treasury stock (22,111) (22,377)

Total stockholders' equity 1,713,191 1,486,839

TOTAL LIABILITIES AND STOCKHOLDERS'

EQUITY $3,252,068 $2,995,359

Roper Industries, Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings (unaudited)

(Amounts in thousands, except per share data)

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Net sales $532,902 $427,217 $1,541,965 $1,235,250

Cost of sales 261,123 208,967 769,643 609,720

Gross profit 271,779 218,250 772,322 625,530

Selling, general and

administrative expenses 158,041 130,730 457,777 385,142

Income from operations 113,738 87,520 314,545 240,388

Interest expense 13,119 11,066 39,957 33,178

Other income/(expense) (404) 267 (1,884) 108

Earnings from continuing

operations before

income taxes
'/>"/>

SOURCE Roper Industries, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Proper Diet Can Counter Macular Degeneration
2. FDA issues warning for Droperidol
3. Tetanus causing toxin has therapeutic properties
4. Compounds Found In The Vegetable Broccoli Could Have Anti-Cancer Properties
5. Geriatric Patients With Chronic Kidney Disease May Not Be Treated Properly
6. The effects of Curcumin: a natural pigment in turmeric explored for its anti-cancer properties
7. Stem Cells, Tumor Cells Share Similar Properties: Scope For Treatment and Prevention?
8. Fruits And Vegetables Have Arthritis Risk Reducing Property
9. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
10. Proper Treatment of Hypothyroidism Found To Prevent Heart Diseases
11. Improperly Placed And Heavy Backpacks Lead To Back Pain In School Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...cientific studies have now reported that exposure ...se the likelihood of sleep disturbance. The cause ...s those from other electrical appliances and high ...ing free radicals in the cerebrospinal fluid (CSF)...sleep-controlling hormone melatonin. , ...
(Date:1/7/2009)... time pancreatic cancer is discovered, it is often...ick Swayze) and survival rates are low. Dr. Aaron...pancreatic, liver and gastrointestinal (GI) cancer...ed a groundbreaking team approach to improve commu...r patients. , Morristow...
(Date:1/7/2009)...ural Alternatives International, Inc. ("NAI") (Nas...and marketer of customized nutritional supplements... its former President, Randell Weaver,s employment...ted certain amendments to its credit facility with...ents extend the maturity date for the working capi...
(Date:1/7/2009)...mbulatory Services of America,Inc. announced the f...h,radiation oncology joint venture. ROSA of South...r Center - Gulf Shores, P.C., Monroeville Radiatio...cology, P.C., and ASA,s,subsidiary, Radiation Onco...ama will own and operate four radiation oncology f...
Breaking Medicine News(10 mins):Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 2Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 3Health News:Nationally-Recognized Pancreatic Cancer Surgeon Develops Unique Team Approach to Improve Patient Outcomes 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2
...entified a new regulatory mechanism in the process...g could open op new // approaches to the treatme...niversity of Bonn, working in collaboration with s...in, have found that mice with a particular gene de...
...he migratory route of wild birds had so far not wi...the latest news about the death of a 14-year-old b...reported only in Asia with the death toll about 70...y denies the rumors about bird flu being the cause...
...eneral practitioner and founder president of the N...Campbell is pioneer // in founding the national a...orant about the health problems involved with obes...ken many people into surprise, though there was lo...
...h it the burden of making resolutions. But how tru...ose weight and look gorgeous at the New Year’s but...when most people actually try to follow through on... a survey. According to a survey by the research ...
Other Medicine News:
(Date:1/7/2009).../ -- ImQuest Life Sciences announced today the suc...od and Drug Administration to initiate human clini...bitor IQP-0410. ImQuest anticipates initiating the...QP-0410 is a novel small molecule inhibitor of HIV...ranscriptase inhibitor (NNRTI). The compound posse...
(Date:1/6/2009)...lts from prior U.S., U.K. and China Trials , , ... Inc. (VTI), a development stage company targeting... has begun for a randomized, controlled, multi-cen...tracorporeal Liver Assist Device (ELAD) as a treat...nder three protocols. The study is open for enroll...
(Date:1/6/2009)...-USNewswire/ -- Sequella, Inc., a clinical-stage b...idemic potential, announced today that SQ109, its ...sis (TB), was the first drug approved for evaluati... Dynport Vaccine Company LLC and Quintiles Transna...itute of Allergy and Infectious Diseases (NIAID), ...
(Date:1/5/2009)...Cylene Pharmaceuticals announced today that it has...2 protein kinase inhibitor, CX-4945, in patients w... multiple myeloma. The primary endpoints of the or...ty, tolerance and PK properties of CX-4945 and to ...n addition, multiple mechanism-related pharmacodyn...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Raydiance collaborates with Rutgers MTF to develop innovative tissue processing approaches 1269 1Raydiance collaborates with Rutgers MTF to develop innovative tissue processing approaches 1269 2MU study finds that sitting may increase risk of disease 1265 1MU study finds that sitting may increase risk of disease 1265 2MU study finds that sitting may increase risk of disease 1265 3New HPV vaccine under study 6618 1New HPV vaccine under study 6618 2Stress hormone may hasten the progression of certain blood cancers 6614 1Stress hormone may hasten the progression of certain blood cancers 6614 2Stress hormone may hasten the progression of certain blood cancers 6614 3
...Kinetics Profile, LAUSANNE, Switzerland, April 19,...), a global independent biopharmaceutical,developm...ditions,presented additional results of a previou...hibitor Debio 025 in HIV/HCV (hepatitis C,virus) c...e 42nd,Annual Meeting of the European Association ...
...USINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,...aceutical,company, discussed results from two pre-...erapy induced angiogenesis and,rationale for combi...spension (paclitaxel protein-bound particles for i...nhibitor drugs like,bevacizumab (Avastin(R)) at th...
Other Medicine Technology:Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 2Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 3Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: